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Abstract
Background—Many HIV-infected pregnant women identified during antenatal care do not enroll 
in long-term HIV care, resulting in deterioration of maternal health and continued risk of HIV 
transmission to infants.
Methods—We performed a cluster-randomized trial to evaluate the effect of integrating HIV care 
into ANC clinics in rural Kenya. Twelve facilities were randomized to provide either integrated 
services (ANC, PMTCT, and HIV care delivered in the ANC clinic; n=6 intervention facilities), or 
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standard ANC services (including PMTCT and referral to a separate clinic for HIV care; n=6 
control facilities).
Results—There were high patient attrition rates over the course of this study. Among study 
participants who enrolled in HIV care, there was twelve month follow up data for 256/611 (41.8%) 
women, and postpartum data for only 325/1172 (28%) women. By 9 months of age, 382/568 
(67.3%) infants at intervention sites and 338/594 (57.0%) at control sites had tested for HIV (OR 
1.45, 95% CI 0.71-2.82); 7.3% of infants tested HIV-positive at intervention sites compared to 
8.0% of infants at control sites (OR 0.89, 95% CI 0.56-1.43). The composite clinical/immunologic 
progression into AIDS was similar in both arms (4.9% vs. 5.1 %, OR 0.83, 95% CI 0.41 - 1.68).
Conclusions—Despite the provision of integrated services, patient attrition was substantial in 
both arms, suggesting barriers beyond lack of service integration. Integration of HIV services into 
the ANC clinic was not associated with a reduced risk HIV transmission to infants and did not 
appear to affect short-term maternal health outcomes.
Keywords
HIV/AIDS; prevention of mother-to-child transmission; service integration; cluster randomized 
controlled trial; Africa
Introduction
The elimination of mother-to-child transmission of HIV (eMTCT) is a top public health 
priority in sub-Saharan Africa.1-4 In order to successfully eliminate vertical transmission and 
to improve maternal health outcomes, all HIV-infected women of child bearing age need to 
be identified through routine HIV testing. However, once identified, HIV-infected pregnant 
women need to navigate a cascade of services5,6 including continued attendance at antenatal 
care (ANC) clinics, enrollment in HIV care, laboratory testing for CD4 count, antiretroviral 
therapy (ART) for the prevention of MTCT throughout pregnancy, labor and delivery, and 
breastfeeding, life-long highly active ART (HAART) for those meeting criteria, and HIV 
testing for HIV exposed infants. Although MTCT has been reduced to < 2% in high-income 
countries7, MTCT rates remain high in most sub-Saharan African countries8, partially 
because women and infants fall out of the cascade at different steps, reducing the 
effectiveness of the interventions5,6,9,10.
In Kenya the majority of pregnant women undergo routine HIV testing as part of antenatal 
care, HIV seropositive women are given PMTCT interventions during antenatal care and are 
then referred to a separate clinic for enrollment in long-term HIV care and treatment.11,12 In 
some settings a pregnant woman diagnosed with HIV will receive care in two clinic 
locations, she will require twice the visits, wait in twice the queues, and have twice the 
number of visits to laboratory or pharmacy. Conversely, women who are established patients 
in HIV clinics may not be routinely evaluated for pregnancy. If a pregnancy is incidentally 
identified, patients are referred to ANC clinics for the duration of their pregnancy, and will 
continue care in two venues.
Family Aids Care and Education Services (FACES) is a U.S. Centers for Disease Control 
(CDC) funded collaboration between the Kenya Medical Research Institute (KEMRI) and 
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the University of California San Francisco (UCSF), which supports the Kenyan Ministry of 
Health to provide HIV care, treatment, and prevention services in Nyanza Province, 
Kenya.13 Over time FACES program managers and national policy makers in Kenya began 
to recognize the missed opportunities and inefficiencies in the vertical systems of care that 
separate ANC, PMTCT, and HIV treatment services. In 2005, FACES program managers 
hypothesized that integrating ANC and HIV treatment services for pregnant women in a 
single clinic with a single provider would result in faster initiation of HAART for eligible 
women and infants, improved maternal health outcomes, and reduced mother-to-child 
transmission of HIV.
Methods
Study Design
This study is a cluster-randomized trial to evaluate the maternal and infant effects of 
integrating ANC, PMTCT, and HIV care and treatment services. Twelve clinics in Nyanza 
Province Kenya were randomized to provide integrated care (intervention arm) that included 
ANC, PMTCT, and HIV care and treatment in the same clinic; or standard of care (control 
arm) that included ANC, PMTCT, and referral for HIV care. All study sites were 
government health facilities that provided ANC, PMTCT, and HIV services with ≥ 20 new 
ANC clients per month. Facilities were stratified as “Health Center/Dispensary” (n = 8) or 
“Hospital” (n = 4) and randomly allocated 1:1 within strata to provide integrated or non-
integrated services using ACluster software. The study enrolled HIV-positive pregnant 
women 18 years and older, not previously enrolled in HIV care, from June 2009 until March 
2011 and followed each mother for one year after enrollment. Infants were followed until 
nine months after delivery. Although providers and patients could not be blinded, study 
investigators were blinded to study outcomes until the study was completed. A complete 
description of the study design and methods has been published previously16.
Study Intervention
At intervention sites ANC providers conducted combined ANC, PMTCT, and HIV care 
visits including enrollment in HIV care, management of HIV disease, management of 
opportunistic infections and HAART if eligible. The same clinician provided all antenatal 
and postpartum services including early infant diagnosis until a definitive pediatric HIV 
diagnosis was obtained or the child reached 18 months of age. At this time the woman and 
infant, if HIV infected, were referred for long-term care to the facility's HIV clinic.
At control sites routine ANC and PMTCT services were provided in the ANC as per 
National Guidelines. Once diagnosed, HIV infected women were encouraged to co-enroll in 
the facility's separate HIV clinic and provided a referral form to facilitate enrollment. 
Women presented separately at these clinics, and HIV clinic providers handled HIV 
enrollment, management of opportunistic infections, and management of HIV disease, 
including HAART if eligible.
Clinicians at each site received a week-long training and on- the-job mentorship with 
periodic refresher trainings on ANC, PMTCT, and HIV treatment, as well as instruction on 
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clinic logistics to improve service utilization for both models. ANC nurses at intervention 
sites received additional training on HIV care and treatment including appropriate disease 
monitoring, treatment of opportunistic infections, prescription of ARVS, and management of 
patients on HAART.
National PMTCT and HIV treatment Protocols
ANC, PMTCT, and HIV services offered at each site followed Kenyan National Guidelines 
in both study arms, with the only difference being the clinic location and the provider of 
HIV care and treatment services for pregnant and postpartum women (ANC clinic versus the 
HIV clinic). National PMTCT protocols mandated that all HIV-positive women should 
receive ARVs for PMTCT, and that a combination of WHO clinical staging and CD4 testing 
was used to determine HAART eligibility. Over the course of the study design and 
implementation, the national PMTCT guidelines changed substantially. From 2007 until 
2010 the National Guidelines recommended maternal zidovudine from 28 weeks gestation, a 
single dose of nevirapine for the mother during labor and for the infant within 72 hours of 
birth. In 2010 the PMTCT guidelines changed to begin maternal zidovudine from 14 weeks 
gestation and added maternal lamivudine and zidovudine for one week in the post partum 
period14. Infant prophylaxis regimens also changed in 2010 from single dose nevirapine 
with four weeks of zidovudine syrup to nevirapine monotherapy until cessation of 
breastfeeding.14 (See Table in supplemental digital content).
National Guidelines for HIV treatment recommended HAART initiation for HIV infected 
pregnant women at WHO clinical stage III or IV regardless of CD4 count, or WHO clinical 
stage I or II with a CD4 count ≤ 350/mm3 throughout the study period. According to 
National Guidelines, women were to receive WHO staging with CD4 testing at baseline and 
every six months thereafter. Adherence to HIV medications and ARVs was assessed by 
patient self-report on history during HIV follow up visits (for women on HAART) or at 
postpartum visits (for women not on HAART).
As part of the HIV care and treatment services substantial attempts were made to find 
patients who missed appointments for HIV follow up. A patient was defined as a “defaulter” 
once they had missed one visit. Defaulter tracing efforts included phone calls and home 
visits by community health assistants. A patient was defined as “lost-to-follow-up” if they 
missed at least one visit, three phone calls had been made, and two home visits were 
conducted at least two weeks apart in attempt to ask the patient to return to clinic. If infants 
had not come for HIV testing by 6 months of age then the defaulter-tracing program was 
also activated to find untested infants.
Study Objectives and Outcomes
The overall study objective was to assess the impact of integrating PMTCT and HIV care 
and treatment in the antenatal care setting on: HIV vertical transmission, maternal HIV 
treatment, infant HIV testing, patient enrollment, retention, adherence, and provider job 
satisfaction. The primary outcome for the study was vertical transmission of HIV. The 
secondary outcomes were mean change in maternal CD4 and WHO stage up to 1 year after 
enrollment, infant HIV testing uptake, HIV care enrollment rates, measures of patient 
Washington et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
retention, and adherence to HIV care compared between intervention and control sites. This 
manuscript focuses the primary outcomes. PMTCT service utilization, HIV care enrollment, 
and adherence outcomes are presented else where in this same issue by Turan J et al. Patient 
and provider satisfaction results were presented elsewhere by Vo B et. al.15
Specifically, the outcomes evaluated in this analysis were: change in maternal CD4 count 
from baseline to study closure, progression of WHO stage from baseline to study closure, 
composite clinical and immunological progression (WHO stage and CD4 count) from 
baseline until study closure, as well as ARV use, and time to HAART initiation. Infant 
outcomes evaluated in this analysis were: uptake of infant HIV testing, HIV incidence at six 
weeks and at study closure (approximately nine months of age), and HIV-free survival of 
infants at study closure.
Power Calculations and Sample Size
The SHAIP trial was powered to detect differences in vertical transmission rates. Power 
calculations for the trial were based on estimated differences in MTCT rates in the two study 
arms, accounting for stratification, based on prior published transmission rates using similar 
protocols for reference.16-18 With a sample size of 12 clusters, 591 HIV-positive women per 
study arm, and an average of 98 HIV-positive women per health facility, we calculated that 
we would have 80% power to be able to detect a minimum odds ratio of 2.02 for vertical 
transmission, assuming an intra-cluster correlation coefficient (ICC) of 0.01.
Data Collection and Data Monitoring Methods
Health facility staff members entered all patient socio-demographic and clinical data on 
paper encounter forms and registers as part of routine clinic care services. Data from paper 
records were entered into an electronic database, which employs the Open Medical Record 
System (OpenMRS®) platform. Study staff extracted data from the Open Medical Record 
System for each SHAIP participant until 12 months after study enrollment. Internal data 
quality monitoring was conducted monthly by the study team, and external data quality 
monitors conducted data quality monitoring semi-annually. Implementation fidelity was 
ensured through a mid-term integration assessment. The assessment demonstrated the 
integration scores of the facilities matched their study assignment, with some variations 
based on the availability of resources.19
Statistical Analysis
Statistical analysis was conducted using an intention-to-treat approach with all analyses 
adjusted for clustering of data within clinics. The comparison of the baseline characteristics 
in the intervention and control sites was done using cluster adjusted chi-square and t-tests. 
Logistic regression within a Generalized Estimating Equations (GEE) framework was used 
to analyze the dependent binary outcomes across the study arms, reporting the odds ratios 
(OR) and respective 95% confidence intervals (CI). Time to event outcomes were analyzed 
using cluster adjusted proportional Hazards Cox regression reporting hazard ratios (HR) and 
respective 95% confidence intervals.
Washington et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Missing data due to patient attrition relative to the measurement of specific outcomes was a 
significant issue in this study because the study relied on routine health facility visits and 
program data. This especially affected analysis of postnatal outcomes and early infant 
diagnosis. We used two methods to deal with missing data. We employed inverse probability 
of censoring weighting (IPCW) to account for potential bias associated with missing 
outcome data, and modeled the probability of remaining in the sample (P(c)) based on 
calendar time and maternal characteristics at baseline. Data were weighted (1/(P(c)) so that 
the distribution of maternal characteristics was similar to the observed data at baseline. 
Additional variables with substantial missing data included dates of birth for infants and 
dates of death for infants who died. To estimate these dates we relied on existing baseline 
data on the woman's estimated date of delivery (EDD) on the study enrollment forms. For 
infant death, an estimate of the date of death was made based on the fact that the majority of 
infant deaths occur during the first month of life. Thus we estimated the date of death at one 
month following the infant's date of birth (or the EDD if date of birth was not available). 
Statistical analyses were conducted using Stata 12 for baseline, time-to-event, and initial 
bivariate analyses, and SAS 9.3 for IPCW analyses.
Ethical Approvals
This study was approved by the Committee on Human Research at the UCSF, the Ethical 
Review Committee at KEMRI and by the U.S. Centers for Disease Control and Prevention. 
All women participating in the study gave written informed consent for the use of their de-
identified data in the study. Participation in the study did not require additional research 
activities beyond women's regular antenatal and HIV care.
Results
1172 pregnant women were enrolled in this study across 12 study facilities. The total 
catchment population in each arm of the study was similar and facility types were balanced 
in each arm in terms of size, level of care, and staffing, as described in our previous 
publication16. Baseline characteristics of the women were not statistically different between 
participants enrolled at intervention and control sites (Table 1).
This study had significant attrition of both mothers and infants (Figure 1). All 1172 
participants had baseline data collected. Among study participants who enrolled in HIV 
care, there was six month follow-up data for 313/611 (51.1%) women, twelve month follow 
up data for 256/611 (41.8%) women, and postpartum data for only 325/1172 (28%) of all 
women. Long term follow up data is not available for study participants who did not enroll 
in HIV care. Postnatal patient records were only available for a small number of study 
participants due to a variety of factors including; women not returning to the clinic following 
delivery, incorrect contact addresses limiting tracing efforts, and incomplete reporting by 
clinicians. Differences in baseline characteristics of women who where lost-to-follow-up and 
women who remained in the study did not reach statistical significance in any parameter 
compared (data not shown).
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ARV use
At baseline 528/569 (92.8%) women received ARVs from the provider in the intervention 
clinics compared to 581/603 (96.4%) women at control clinics (OR 0.53, 95% CI 0.28 - 
1.02). However, among the subgroup of women with data on self-reported ARV adherence 
(including women on HAART) collected at the postpartum visit (n=329), the proportion of 
women who reported completing the national PMTCT protocol and swallowed ARVs for 
PMTCT across the antepartum, intrapartum, and postpartum periods was very low in both 
arms and not significantly different in intervention 37/176 (21%) versus control clinics 
23/153 (15%)(OR 1.72, 95% CI 0.85 - 3.48). In this same subgroup, the proportion of 
women who had reported swallowing only intrapartum and postpartum ARVs (incomplete 
PMTCT intervention) was lower in intervention [19/176 (11%)] compared to in control sites 
[60/153 (40%)], although this difference was not statistically significant (OR 0.39, 95% CI 
0.11 - 1.36). Despite dispensing ARVs to a high proportion of women, 184/ 476 (39%) 
women reported after delivery (either at a postpartum visit or HIV follow up visit) that they 
had not swallowed any ARVs for PMTCT or HAART at any point during the study period 
(either antepartum, intrapartum, or postpartum); the proportion was not associated with 
study arm (OR 0.934, 95% CI 0.42 – 2.06).
Among women who were eligible for HAART, only 88/239 (37%) women initiated HAART 
during pregnancy (defined as women who received at least two weeks of HAART prior to 
delivery),more initiated at intervention sites [66/143 (46%)] compared to control sites [22/96 
(23%)](OR 2.37, 95% CI 1.06 - 5.27). In addition, the median time to HAART initiation, 
among eligible women, was shorter in the intervention arm [125 days (interquartile range 
(IQR) 35-273)] compared to the control arm [185 days (IQR 83-316)] (HR=2.74, 95% CI 
1.56-4.80). (Figure 2)
Maternal health outcomes
The maternal outcomes evaluated included changes in clinical and immunologic status 
between intervention and control sites. However, we only had both baseline and follow up 
absolute CD4 count on 216/1172 (18.4%) and WHO staging for both baseline and follow-up 
on 315/1172 (26.9%) of women. Among these women, we did not find significant 
differences between study arms in change in CD4 count, progression to WHO stage 3 or 4 
disease, or in combined clinical/immunologic progression to AIDS from baseline to study 
close (Table 2).
Infant outcomes
There was a high loss-to-follow-up rate of infants in both arms and as a result there were low 
levels of infant testing in both study arms. At six weeks more infants had undergone PCR 
testing in the intervention compared to control sites 43/568 (25%) vs. 106/594 (18%) (OR 
1.57, 95% CI 0.61 - 4.07). By the end of the study, a slightly greater proportion of HIV-
exposed infants had undergone HIV testing at intervention sites [382/568 (67.3%)] 
compared to control sites [338/594 (57.0%)](OR 1.45, 95% CI= 0.71-2.82), however these 
trends did not reach statistical significance.
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Infant HIV-infection by six weeks of life (4.2% in intervention sites vs. 6.6% in control sites, 
OR 0.62, 95% CI 0.20–1.90) and at the end of follow up at nine months (7.3% in 
intervention sites vs. 8% in control sites, OR 0.89, 95% CI 0.56 - 1.43) did not differ by 
study arm (Table 3). We performed a sensitivity analysis to account for the substantial 
amount of missing infant HIV testing data due to low uptake of early infant diagnosis at the 
clinics. After adjusting for missing data the odds of infant infection at six weeks and at nine 
months showed similar odds as those obtained from the unadjusted analysis. Overall infant 
mortality rates and HIV-free survival did not differ significantly by study arm (Figures 3 & 4 
in Supplemental Digital Content).
Multivariable analyses examining the impact of censoring showed that adjustment for loss-
to-follow-up did not significantly change the results. Inverse probability of censoring 
weighting (IPCW) results were of similar direction, magnitude, and statistical significance to 
the initial analytical results for variables that had substantial missing data due to loss-to-
follow-up including infant feeding method and infant HIV testing uptake. These results are 
presented in Table 3.
Discussion
To our knowledge, this study represents the first cluster randomized controlled trial with the 
specific aim to evaluate integrated ANC and HIV treatment for HIV infected pregnant 
women in sub-Saharan Africa. Currently, public health officials are looking for strategies to 
eliminate vertical transmission of HIV and, despite a lack of compelling data, integration of 
care has been proposed as a key strategy in the fight for eMTCT.1,4,20-22
This paper focuses on the infant transmission outcomes and maternal health outcomes 
associated with full integration of ANC, PMTCT, and HIV care. A separate manuscript 
published in this issue demonstrated that integration was associated with improved uptake of 
some key services along the PMTCT cascade. [Reference once published] In addition, we 
have previously found a high degree of both patient and provider acceptability with 
integration, and indications that providers prefer an integrated model of care in the 
ANC.15,23
In this study, over 90% of women were given ARVS at their first visit, however amongst 
women who came for postpartum visits, there was a substantial proportion of women (39%) 
who self-reported not taking ARVS. This suggests that there may still be substantial 
adherence barriers that have not been explained in this study.
Although the time to initiation of HAART among eligible pregnant women was shorter at 
intervention compared to control sites, based on the median time to HAART initiation (125 
days) and the mean gestational age at enrollment (26 weeks), assuming a 40 week 
gestational period it appears that most women in both arms did not start HAART until the 
post-partum period. In addition, we did not find a statistically significant difference in 
vertical HIV transmission between study arms. Approximately half of women in Kenya, like 
many countries in the region, begin prenatal care in the third trimester of pregnancy.24 
Therefore, even though some women were eligible to start HAART during pregnancy as per 
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WHO and Kenyan National guidelines, most women did not initiate HAART until post-
partum. This represents an enormous missed opportunity to further decrease mother-to-child 
transmission by using more effective regimens for sicker patients. Delay in HAART 
initiation may have been due to the need to draw baseline labs, including CD4 testing prior 
to HAART initiation, which can create significant delays in a rural setting where lab 
specimens must travel to a central lab for processing. (In study facilities CD4 results took 
approximately one month to return to facility). The delay in HAART initiation may have 
also been due to the clinic requirements for patients to undergo three adherence counseling 
sessions prior to HAART initiation which may also represent an undue visit burden on 
patients. The lengthy time to HAART initiation in both study arms, and the lack of 
difference in infant transmission rates between study arms, may serve as indirect evidence to 
support a more streamlined approach to HAART initiation during pregnancy whereby 
women who are diagnosed with HIV during pregnancy are started at the same visit on 
HAART without laboratory investigations (a strategy know as WHO Option B+).25 
However, in order to implement Option B+ a significant increase in staff, clinical tools, 
adherence support, and community follow up systems will need to be in place to adequately 
follow the increased numbers of patients on HARRT.
In addition, this study may have failed to show a difference in vertical transmission due to a 
rapidly changing health policy environment regarding PMTCT. Over the course of the study 
national PMTCT protocols changed, which may have biased the results towards the null 
given that both intervention and control arms offered more effective PMTCT drug regimens 
during the latter half of the study.14 Improved PMTCT drug regimens are associated with 
decreased transmission rates7 and thus our study, although initially adequately powered to 
detect a difference in transmission may have become underpowered as national PMTCT 
regimens improved in Kenya.
This study also did not demonstrate any difference in maternal health outcomes over the 
course of the study period. This is likely due to the short follow up period of one year and 
the amount of missing data in both study arms. Given the healthy state and relatively high 
CD4 counts at enrollment in both arms, it was unlikely that any clinically significant 
differences in maternal morbidity or mortality could be demonstrated over such a short time 
period.
This study used patient data from a public HIV treatment program and the results inherently 
include all of the challenges and pitfalls of program implementation in a rural African 
setting. The challenges included training and retaining providers, incomplete record keeping, 
missing data, and problems with data quality. Other challenges included assuring that 
patients received care per national PMTCT protocols, as well as challenges in patient 
follow-up and retention in care. This study suffers from a high loss-to-follow-up rate 
(25-30%) in both arms. Although the data are imperfect, which is a major study weakness, 
they are also reflective of the real-world setting of programs in rural Africa and thus may 
have wider reaching validity and generalizability for program managers and implementers 
than that of a controlled clinical trial setting. As greater investments to healthcare systems 
and improvements to medical records systems are made in public health facilities, using 
patient records from public programs for research may become more feasible.
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Despite limited evidence,20,22 integration of ANC, PMTCT and HIV services has been 
promoted by the WHO and Ministries of Health across much of sub-Saharan Africa as a 
strategy to help achieve the elimination of MTCT.4,26-32 In 2009, the NIH Office of AIDS 
Research identified as a top priority research on how to promote women's linkage to and 
retention in care at each step of the PMTCT cascade.33 This study demonstrates that 
although we are able to enroll more women in HIV care through integration, integration 
alone does not necessarily translate to improved maternal health outcomes or decreased rates 
of mother-to-child transmission of HIV, as compared to non-integrated services. If anything 
this study implies that integration may be necessary, but is not sufficient, in order to achieve 
eMTCT and more streamlined approaches to encourage rapid HAART initiation for all 
pregnant women should be developed, implemented, and rigorously evaluated.
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Figure 1. Diagram of study recruitment, enrollment, and infant follow up at intervention and 
control sites
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Figure 2. Time to HAART Initiation for Eligible Women
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Table 1
Comparison of baseline patient characteristics among intervention and control sites
Intervention (n=569) Control (n=603) P value Number (%) with missing data
Mean age in years (SE) 25.0 (0.19) 24.8 (0.18) 0.582 6 (0.51)
Education, n (%) 2 (0.17)
 None or Some Primary 481 (85%) 533 (89%) 0.372
 Some Secondary or more 84 (15%) 68 (11%)
Marital status, n (%) 10 (0.85)
 Married 472 (84%) 500 (84%) 0.986
 Single/Separated/Divorced 49 (8%) 50 (8%)
 Widowed 43 (8%) 48 (8%)
Median Gravidity (IQR) 3 (2-4) 3 (2-4) 0.943 19 (1.62)
Median Parity (IQR) 2 (1-3) 2 (1-3) 0.921 25 (2.13)
Mean Gestational Age, weeks (SE) 26 (0.3) 25.2 (0.3) 0.100 10 (0.85)
WHO stage n (%) 66 (5.63)
 WHO Stage 1 339 (63%) 455 (80%) 0.403
 WHO Stage 2 79 (15%) 42 (7%)
 WHO Stage 3 or 4 31 (6%) 8 (1%)
 Not Staged 85 (15%) 67 (12%)
Mean Baseline CD4 (SE) 495 (19.87) 523 (19.18) 0.336 508 (43.34)
Baseline CD4 category
 ≤350 117 (34%) 96 (30%) 0.654
 351-499 79 (23%) 83 (26%)
 ≥500 146 (43%) 143(44%)
Eligible for HAART 127 (22%) 87 (14%) 0.278 0
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Table 2
Comparison of maternal disease outcomes among intervention and control sites N= 1172
*OR are adjusted for cluster effects
‡Result obtained using Inverse probability of censoring weighting (IPCW)
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Table 3
Comparison of infant outcomes among intervention and control sites N=1172
*OR are adjusted for cluster effects
†By patient report (out of 325 women with postpartum forms)
‡Result obtained using Inverse probability of censoring weighting (IPCW)
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